The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Open interest data suggests the advance is likely short-covering, rather than fresh longs entering the market.

BTIG raised Praxis Precision Medicines Inc (NASDAQ: PRAX) price target from $507 to $843. BTIG analyst Kambiz Yazdi ...

British American Tobacco p.l.c. (NYSE:BTI) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. On ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. The Velo 1, made by Philips in 1997, ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

In December 2025, Genentech, part of the Roche Group, received U.S. FDA accelerated approval for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab for adults with relapsed or refractory ...

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears ...

Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for ...

Velo’s integration of the USD1 stablecoin with World Liberty Financial will help to strength its liquidity and settlement ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...